Military Medical Provider Defense

DHA-PM 6025.13 - PEER REVIEW HEARING LAWYER

Military Doctor Defense Attorney | Global DHA & NPDB Representation

Representing US Army, Navy, and Air Force Healthcare Providers (Uniformed, civilian, Contractor) at MTFs Worldwide – From Landstuhl to Okinawa and across the United States.

Clinical Adverse Actions and Adverse Privileging Actions for privileged providers are governed by DHA-PM 6025.13, Volume 3 as of October 1, 2019.

Free Case Consultation

Summarily suspended? Let Korody Law provide you a free case consultation.

Experience Defending Military Healthcare Providers Since 2009

Attorney Patrick Korody has represented military healthcare providers in clinical privileging and adverse action matters since 2009.  Over the past decade, since opening his military law firm Korody Law, PA, Mr. Korody handled cases across every service component — Army, Navy, and Air Force — both under the prior service-specific legacy regulatory systems (MEDCOM, BUMED, AFMOA/AFMS) and under the current Defense Health Agency (DHA) framework governed by DHA-PM 6025.13.

His practice has included representation of surgeons and surgical subspecialists, anesthesiologists and CRNAs, emergency physicians, primary care providers, behavioral health professionals (psychologists, psychiatrists, licensed clinical social workers), dentists, pharmacists, registered nurses, and advanced practice nurses. These cases have arisen at major military medical centers, community hospitals, and overseas military treatment facilities.

The allegations in these matters have spanned the full spectrum of patient safety and MHS integrity claims: clinical incompetence, deviation from the standard of care, impairment concerns, prescribing disputes, documentation deficiencies, professionalism complaints, interpersonal co-worker allegations, and broader claims of professional misconduct to include sexual assault and theft of drugs. Some cases involved isolated clinical events; others involved pattern-based peer reviews or departmental conflict.  Many involved claims of failed focused professional proficiency evaluations (FPPE).

Attorney Korody has represented providers through every phase of the DHA privileging process, including summary suspensions, Quality Assurance Investigations (QAI), proposed adverse privileging actions, peer review panel hearings, appeals to the report authority (Director, DHA or service Surgeon General), and post-decision strategy related to National Practitioner Data Bank (NPDB) reporting and state licensure. He has also advised providers on reinstatement strategy, especially when it is reinstatement with monitoring and evaluation) and scope-of-practice restructuring designed to preserve long-term credentialing stability and avoid future allegations.

Having practiced during the era when each service maintained its own privileging systems, Mr. Korody understands both the legacy service culture that still influences investigations and the centralized DHA structure that governs today’s process.

These cases are rarely about perfection. They are about whether the care provided met an appropriate and realistic standard under the circumstances. QAI investigating officers often want to sound like the authority on the issue and apply hindsight analysis, impose a “perfect” standard, or assume there is only one acceptable way to practice–a recurring problem with military-trained medical professionals.  Effective defense requires disciplined record analysis, careful articulation of the applicable standard of care, and strategic navigation of administrative decision-making dynamics.

In the summary suspension stage, providers often feel like there is no hope and no avenue to fight back against the DHA.  Mr. Korody’s role is to fight back for his clients.   At the peer review hearing stage, that often means presenting overwhelming evidence in support of the provider’s care, including detailed documentation, patient records, policy materials and clinical practice guidelines, witness testimony, and, where appropriate, independent expert analysis.  Mr. Korody exposes flawed standards and representations in the QAI and demonstrates that the provider is safe and competent and that there should be no concerns about the provider’s ability to practice in the MTF.

Why You Need an Experienced Lawyer at a DHA Peer Review Hearing

A DHA Peer Review Hearing is not a routine meeting. It is a formal administrative adjudication conducted under DHA-PM 6025.13, transcribed verbatim for the official record, and governed by defined procedural rules. Witnesses testify under oath. Exhibits are formally admitted. Objections are ruled upon. A panel deliberates and issues written findings and recommendations.

The panel applies a preponderance of the evidence standard — meaning it need only conclude that an allegation is more likely than not true. That lower burden makes structured advocacy critical. Once the record is created, it becomes the foundation for the panel’s recommendation, the Privileging Authority’s decision, and potentially National Practitioner Data Bank (NPDB) reporting.

After the hearing concludes, the Peer Review Panel is required to deliberate and prepare written findings and a recommendation — typically within 30 days. What happens during the hearing directly shapes what goes into that report.

Panel Selection and Challenges (Voir Dire)

Before evidence is presented, panel members are sworn and questioned to determine whether they can serve fairly and impartially. This stage functions much like voir dire in court.

A provider has the right to challenge panel members for cause if bias, prior involvement, or a predisposed attitude exists. An experienced attorney knows what to probe, what answers matter, and when to challenge. Panel composition can influence how clinical judgment, documentation, and standard-of-care disputes are evaluated.

Opening Statement: Setting the Battlefield

The MTF will present its case in a structured manner, often relying heavily on the QAI findings. If that narrative is not immediately reframed, it becomes the baseline from which the panel views the entire case.

A strong opening statement establishes:

  • The correct and realistic standard of care
  • The difference between clinical judgment and incompetence
  • Why hindsight cannot substitute for contemporaneous decision-making
  • Why a “perfect” or dogmatic standard is legally and medically improper

Without disciplined advocacy at the outset, the panel may unconsciously adopt the MTF’s framing before the defense evidence is even heard.

Cross-Examination and Witness Control

Witnesses testify under oath. The MTF presents first. The provider has the right to question each witness.

Effective cross-examination can:

  • Expose inconsistencies in the QAI
  • Highlight incomplete record review
  • Clarify that multiple reasonable clinical approaches exist
  • Demonstrate bias or methodological flaws
  • Undermine “perfect standard” reasoning

Panel members may question witnesses directly. An experienced lawyer ensures those exchanges remain focused, clinically grounded, and aligned with the applicable standard of care.

Documentary Evidence and Objections

The MTF typically introduces key exhibits, including the summary suspension memorandum, QAI report, credentials committee recommendations, clinical activity files, and credentialing records.

Because the hearing is administrative and not bound by strict courtroom evidence rules, panels may consider information that would not be admissible in court. That makes strategic objection and record control essential.

Counsel may object to:

  • Irrelevant or prejudicial material
  • Expansion beyond the scope of the notice
  • Misstatements of the applicable standard of care
  • Procedural irregularities affecting due process

Protecting the integrity of the record at the hearing stage is critical because appeals are limited and deferential to the existing record.

The Possible Recommendations — And What They Mean

After deliberation, the panel must recommend one of the following outcomes:

  • Reinstatement of Privileges: Full restoration of previously granted privileges. No adverse action.
  • Reinstatement with Monitoring (FPPE or M&E): Return to practice with structured monitoring and defined performance metrics. This is not considered an adverse action but must be successfully completed.
  • Restriction of Privileges: Temporary or permanent limitation requiring supervision or concurrence for certain procedures. A written supervision plan is required.
  • Reduction of Privileges: Permanent removal of a portion of privileges. The provider may no longer perform those services — even under supervision.
  • Revocation of Privileges: Permanent removal of all clinical privileges and removal from patient care duties.

Restriction, reduction, or revocation — if approved by the Privileging Authority — may result in reporting to the NPDB and notification to licensing authorities.

This Is the Decisive Moment

The hearing is often the most important opportunity to influence the outcome of a privileging case. The panel’s written findings — issued after deliberation — shape everything that follows: final action, reporting decisions, and long-term credentialing consequences.

A DHA Peer Review Hearing is not a venue to “explain and hope.” It is a structured evidentiary proceeding that requires strategic voir dire, disciplined opening advocacy, precise questioning, controlled objections, and organized presentation of documentation, patient records, witnesses, and — where appropriate — expert testimony.

The quality of the advocacy at this stage can materially affect not only the recommendation, but the trajectory of a provider’s entire professional career.

Consequences of a Final Adverse Privileging Action

  • Privileges will be denied, suspended, restricted, reduced or revoked.
  • Military members may be processed for involuntary separation from the service with a less than Honorable discharge.
  • Civilians and contractors may have employment terminated.
  • The action will be reported by the Defense Health Agency to the National Practitioner Data Bank (NPDB) and state licensing authorities, impacting future employment and earnings.

Adverse Privileging Action Frequently Asked Questions (FAQ)

What is a summary suspension?  A summary suspension is a removal from clinical practice and usually the first indication that the provider is being investigated for clinical incompetence, impairment, or professional misconduct. The provider will receive formal written notice that that includes certain rights as outlined in DHA-PM 6025.13, Volume 3.

Can I quit if I am under a summary suspension? An employee like a contractor or civilian employed “at will” of course can quit.  A military member could request to separate.  A civilian or military member should rarely quit or separate while under a summary suspension, but this is a very case-by-case determination.  Contractors tends to get fired or go into an unpaid status so the decision to quit is often one made for them.  Most importantly, any provider under a summary suspensions who ends affiliation (quits, terminated, separated) must, in writing, immediately request that the due process procedures continue.  This is normally accomplished by an email or letter to the point of contact identified in the summary suspension.

If I quit before I am placed in a summary suspension, can they investigate me?  Not only can you be investigated, they can follow the whole process and seek to adjudicate a final adverse privileging action.  If you have ended affiliation and receive notice by mail or email that you are the subject of a quality assurance investigation (QAI) it is important to respond and request due process procedures.

Will the summary suspension be reported to the NPDB?  After 30 days, the summary suspension will be reported to the NPDB.  A revision-to-report will thereafter be made when the process concludes updating the entry to show the final decision, whether it be reinstatement or a adverse clinical action.  I do not believe DHA is following the NPDB regulations with respect to entering and removing summary suspensions from the NPDB and am actively challenging this reporting.  In my experience, it is exceedingly rare than a provider is reinstated before the 30 days elapses.

What are my rights in this process?  A provider has many rights under DHA-PM 6025.13, Volume 3, though the regulation can be confusing and contradictory in parts.  The three most important rights are 1) the right to receive and respond to the QAI before it goes to the privileging authority; 2) the right to appear before a Peer Review Hearing; and 3) the right to appeal the privileging authority’s final decision to the DHA.  There are also separate rights under the regulations governing the NPDB to submit a statement or appeal a NPDB entry.

When should I hire a lawyer?  You should, at minimum, speak to a lawyer experienced in handling adverse privileging action cases when you receive the summary suspension.  You should hire an experienced lawyer if you receive the QAI and finds incompetence, impairment, or misconduct. 

How can a lawyer help me?  We can assist you in exercising your rights and challenging the allegations made against you.  A Peer Review Panel Hearing is like a mini-trial.  Evidence is admitted.  Witnesses are called. Opening and closing arguments are made.  Your lawyer actively represents you and challenges the allegations and proposed adverse clinical action.  If an appeal is necessary, your lawyer will obtain and review the hearing transcripts and draft an appeal alleging legal errors in the process and making equity arguments against an adverse clinical action.

The biggest mistake providers make is thinking they can talk their way to immediate reinstatement when notified of a summary suspension of privileges.  That "talking" often is more harmful than helpful.

Patrick Korody
Attorney and Firm Founder

Free Case Consultation

Summarily suspended? Let Korody Law provide you a free case consultation.